Log in  First Connection?

Prostate Cancer & BPH: Archives News of the month

The impact of prostate volume on Retzius-sparing robot-assisted laparoscopic radical prostatectomy with retrograde release of the neurovascular bundle

 Published on 04/04/2025 |  Original article (Abstract)  | Liu Yang et al. | BMC Urology 2025; 25(1): 59

Nowadays, prostate cancer has become one of the most common malignant tumors [1]. Robot-assisted radical prostatectomy (RARP) is the standard treatment for localized prostate cancer [2]. Compared to traditional open and laparoscopic surgery, it has obvious advantages in tumor control, potency preservation,...

The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

 Published on 28/03/2025 |  Original article (Abstract)  | Sekine Yoshitaka et al. | BMC Cancer 2025; 25(1): 521

Androgen deprivation therapy plays an important role in the treatment of metastatic prostate cancer. In addition, new anti-androgen therapies, such as enzalutamide, abiraterone, apalutamide, and darolutamide, have been introduced for castration-resistant prostate cancer (CRPC) [1, 2, 3–4]. However,...

Associations between green tea drinking and body mass index, serum lipid profile and prostate-specific antigen in a Ghanaian population: a cross-sectional study

 Published on 21/03/2025 |  Original article (Abstract)  | Ntim Emmanuel Amankwah et al. | BMC Nutrition 2025; 11(1): 55

Prostate cancer is the second most diagnosed cancer in men globally and the fifth leading cause of death worldwide [1, 2]. Men of African ancestry suffer the most aggressive type of this cancer, leading to the highest mortality-to-incidence rate ratios globally compared with other ethnicities [3, 4]....

Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings

 Published on 14/03/2025 |  Original article (Abstract)  | Peng Yiji et al. | BMC Urology 2025; 25(1): 42

Prostate cancer (PCa) is the second most commonly diagnosed solid malignancy worldwide, with an ever-increasing incidence [1]. The definitive diagnosis of prostate cancer relies on histopathological verification through prostate biopsy. Currently, the indication for prostate biopsy is determined by prostate...

Urinary function, sexual function and quality of life after prostate low-dose-rate brachytherapy: a retrospective analysis

 Published on 07/03/2025 |  Original article (Abstract)  | Mäkelä Lauri et al. | BMC Urology 2025; 25(1): 40

Most cancer treatments carry adverse effects that significantly impact patients' quality of life. The careful estimation of the risks and benefits associated with each treatment option is especially important for cancer patients who are being offered curative treatment. This is especially relevant for...